Publications and Presentations

Filter By:

Selumetinib

06/01/2013

American Society of Clinical Oncology Annual Meeting

Phase II Study of Selumetinib vs Temozolomide in Patients with Advanced Uveal Melanoma (CTEP #8443)

R. D. Carvajal

ARRY-502

05/13/2013

American Thoracic Society International Conference

Th2 Signature Selection Strategies for CRTh2 Antagonists: Baseline Characteristics of a Mild to Moderate Persistent Asthma Population

D. Chantry, et al.

ARRY-614

04/06/2013

American Association for Cancer Research Annual Meeting

The Design and Early Development of the P38/Tie-2 inhibitor, ARRY-614 in Hematologic Cancers

K. Koch Ph.D.

Filanesib

04/04/2013

International Myeloma Workshop

Single-Agent Activity of the Novel KSP Inhibitor ARRY-520 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from Subgroup Analyses

S. Lonial, M.D. et al.

Filanesib

04/04/2013

International Myeloma Workshop

A Phase 1 Study of ARRY-520 with Bortezomib in Relapsed or Refractory Multiple Myeloma

A. Chari, M.D., et al.

Binimetinib

02/13/2013

The Lancet Oncology

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

P. A. Ascierto, et al.

Selumetinib

12/21/2012

The Lancet Oncology

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

J. Farley, et al.

Filanesib

12/10/2012

American Society of Hematology Annual Meeting

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

J.J. Shah, MD, et al.

Filanesib

12/10/2012

American Society of Hematology Annual Meeting

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

J.J. Shah, MD, et al.

ARRY-614

12/09/2012

American Society of Hematology Annual Meeting

Role of p38 MAPK and Tie2 in the Pathogenesis of MDS and Their Inhibition by Dual Inhibitor ARRY-614

S. L. Winski, et al.